Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Gastroenterology

Volumn 125, Issue 2, 2003, Pages 292-297

  Angus, Peter ^a,d   Vaughan, Rhys ^a   Xiong, Shelly ^b   Yang, Huiling ^b   Delaney, William ^b   Gibbs, Craig ^b   Brosgart, Carol ^b   Colledge, Danielle ^c   Edwards, Rosalind ^c   Ayres, Anna ^c   Bartholomeusz, Angeline ^c   Locarnini, Stephen ^c  

^a AUSTIN HEALTH   (Australia)

^b GILEAD SCIENCES   (United States)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARAGINE; BILIRUBIN; HEPATITIS B VIRUS POLYMERASE; LAMIVUDINE; PROTHROMBIN; THREONINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BACULOVIRUS; CASE REPORT; DISEASE ACTIVITY; DNA SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTHROMBIN TIME; SITE DIRECTED MUTAGENESIS; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

EID: 0041853784     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00939-9     Document Type: Article

References (29)

1. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis 2003;23:69-79.
2. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-88.
3. Adefovir Dipivoxil 438 Study Group, Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
4. Adefovir Dipivoxil 437 Study Group, Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
5. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
6. Yang H, Westland CE, Delaney WE IV, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
7. Mailliard MS, Gollan JL. Suppressing hepatitis B without resistance. So far so good. N Engl J Med 2003;348:848-850.
8. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624.
9. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-1153.
10. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-245.
11. Chen R, Edwards R, Shaw T, Colledge D, Delaney WE IV, Isom H, Bowden S, Desmond P, Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37:27-35.
12. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501.
13. Delaney WE IV, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45:1705-1713.
14. Lewin S, Ribeiro RM, Walter T, Lau GKK, Bowden DS, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1120.
15. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadanaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-225.
16. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadna viral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000;44:551-560.
17. Delaney WE IV, Westland CE, Yang HL, Link KY, Das K, Arnold E, Jain AK, Miller MD, Gibbs CS. Cross-resistance analysis of lamivudine, adefovir, and entecavir using a cell culture model of HBV replication (abstr). Antiviral Res 2001;50:A81.
18. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995;69:5437-5444.
19. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Miller M, Gibbs CS, Xiong S. Functional analysis of rt V173L on HBV polymerase mutation frequently observed in lamivudine-resistant chronic hepatitis B patients (abstr). Hepatology 2002;36(Suppl): 373A.
20. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
21. Bartholomeusz A, Schinazi R, Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepat Rev 1998;4:167-187.
22. Bartholomeusz A, Groenen L, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology 1997;40:337-342.
23. Mulato AS, Lamy PD, Miller MD, Li WX, Anton KE, Hellmann NS, Cherrington JM. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998;42:1620-1628.
24. Foli A, Sogocio KM, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H, Yarchoan R. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy) ethyljadenine (PMEA). Antiviral Res 1996;32:91-98.
25. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM, Wainberg MA. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 1995;39:1888-1891.
26. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-4779.
27. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137.
28. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-3734.
29. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000;32:430-432.